Intravenous bispecific monoclonal antibody (T‑cell engager) that binds BCMA on plasma cells and CD3 on T cells, redirecting T‑cell cytotoxicity to deplete pathogenic plasma cells and reduce amyloidogenic light‑chain production in systemic AL amyloidosis. Also known as REGN5458; brand name Lynozyfic.
Bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, redirecting T‑cell cytotoxicity to deplete BCMA+ plasma cells and reduce amyloidogenic light‑chain production in AL amyloidosis.
NO
INDIRECT
CD3 is on T cells; linvoseltamab engages CD3 to activate T cells, which kill BCMA+ plasma cells via perforin/granzyme-mediated cytotoxicity. CD3+ cells are not the killed targets.
Subcutaneous anti-CD38 IgG1 monoclonal antibody targeting CD38 on plasma cells; mediates ADCC, CDC, ADCP, and apoptosis, and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs).
Human IgG1 monoclonal antibody targeting CD38 that binds CD38 on myeloma/plasma cells and CD38+ immunosuppressive cells, inducing direct apoptosis and Fc-mediated cytotoxicity (ADCC, CDC) and phagocytosis (ADCP), leading to depletion of CD38-expressing cells and enhanced antitumor immunity.
YES
DIRECT
Daratumumab binds CD38 on target cells and induces direct apoptosis and Fc/complement-dependent killing (NK-cell ADCC, macrophage ADCP, and CDC), depleting CD38+ cells.
A STEAP1-targeted antibody–drug conjugate (ADC) that binds STEAP1 on tumor cells and, upon internalization, releases a cytotoxic payload to selectively kill STEAP1-expressing cancer cells.
A STEAP1-targeted antibody-drug conjugate that binds STEAP1 on tumor cells, is internalized, and releases an intracellular cytotoxic payload to selectively kill STEAP1-expressing cancer cells.
YES
DIRECT
The ADC binds STEAP1 on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills STEAP1-expressing cells (e.g., via microtubule disruption or DNA damage).
Anti-CD20 monoclonal antibody that depletes malignant B cells via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and eliminates CD20-positive malignant and normal B cells primarily via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity (CDC), and direct apoptotic signaling.
HER2-targeted monoclonal antibody that blocks HER2/ErbB2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized monoclonal antibody against HER2 (ErbB2) that binds the extracellular domain, blocks receptor dimerization and downstream PI3K/AKT and MAPK signaling, promotes HER2 downregulation, and mediates antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
Fc-mediated ADCC: trastuzumab binds HER2 on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells/macrophages) to lyse the bound cell; it also blocks HER2 signaling and promotes downregulation/apoptosis.